Amgen isn’t wowing ESMO with the latest KRAS G12C update — but maybe there are more important issues at stake
BARCELONA — Amgen isn’t going to blow anybody away with its latest cut of the Phase I data on its closely followed KRAS G12C program. But with the whole biopharma world watching every cut of the data, down to the last partial response, they make the argument that every step in the journey has some important lessons to offer in opening the door to a brand new field.
In an update Saturday morning at the big annual ESMO meeting in Barcelona, the pharma giant says that researchers recorded a single partial response among the 12 colorectal cancer patients with the KRAS G12C mutation who had been given AMG 510. In addition, one of 2 cases of treatment-resistant cases of appendiceal cancer also demonstrated a response.
That may well further tamp down on the effervescent market response that greeted Amgen’s first snapshot of promising data on non-small cell lung cancer, where 3 of 3 patients in the high dose demonstrated a response — cut down to 54%, or 7 of 13, in the most recent update available.
“Obviously lung cancer seems to be the strongest signal,” says Greg Friberg, the head of Amgen’s oncology development group and an avowed enthusiast here.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,600+ biopharma pros reading Endpoints daily — and it's free.